Determining level of endogenous serum erythropoietin for differential diagnosis of polycythemia vera and symptomatic polycythemia
DOI:
https://doi.org/10.26641/2307-0404.2013.2.15950Keywords:
erythropoietin, polycythemia vera, secondary erythrocytosisAbstract
The article deals with determining possibility of the assessment
of the level of endogenous serum erythropoietin (EPO) for differential diagnosis of polycythemia vera (PV) and
secondary erythrocytosis (SE). The determination of subnormal level of this cytokine for the diagnosis of PV has been
detected. The relation between the level of endogenous erythropoietin and iron metabolism also has been analyzed. The
study involved 88 patients with PV and 119 patients with SE. Statistically significant decrease in EPO concentration
level has been detected in PV patients. The mean EPO level was equal to 6.38 ± 0.84 mIU/mL and 17.98 ±2.48 mIU/mL
in PV and SE patients respectively. In control group of individuals EPO concentration was equal to 9,81 ±0,58
mIU/mL, the significant difference was found between all studied groups (р<0.01). According to our data, EPO was
increased in 28 SE patients (23.53%), it was not observed in control group and in group of PV patients
(φ*emp = 4.355, р<0.01). The decrease of EPO level in PV patients has been detected more often than in SE patients
(84.09% versus 11.76% , φ*emp = 5.218, р<0.01), it has not been observed in control group. Only 14 (15.91%) PV
patients had normal EPO level, in contrast 77 (64.71%) SE patients demonstrated normal EPO level (φ*emp = 4.578,
р<0.01). The average level of ferritin was equal to 57.41 ± 9.74 ng/mL in PV patients and 199.77 ± 14.32 ng/mL in SE
patients (р<0.01). Significantly more patients with PV demonstrated decrease of ferritin level (31.81% versus 7.56%,
φ*emp = 4.438, р<0.01). Patients with SE more often had raised level of EPO than PV patients (15.12% versus 4.54%,
φ*emp = 2.453, р<0.01). The sensitivity of test with detecting of the reduced level of EPO for the diagnosis of PV was
84.1%, specificity - 87.4%, positive predictive value - 83.1%, negative predictive value - 88.1%. Normal range of EPO
significantly (rs = 0,5494) correlated with decreased levels of serum ferritin in patients with polycythemia vera, which
was caused by iron deficiency in a certain number of patients with PV.
References
Румянцев А.Г. Эритропоэтин. Биологические свойства. Возрастная регуляция эритропоэза. Клини-ческое применение / А.Г. Румянцев, Е.Ф. Морщакова, А.Д. Павлов. - М.: Гэотар -мед, 2002. – 399 с.
Танасийчук И.С. Алгоритм оценки эффек¬тив-ности диагностических критериев / И.С. Танасийчук // Укр. журнал гематології та трансфузіології . – 2010. - № 4. – С. 35-39.
Alman, D.G. Diagnostic test.1: sensitivity and spe-cificity / D.G. Alman, J.M. Bland // BMJ. – 1994. – Vol.308. – P. 1552.
Diagnostic value of serum erythropoetin level in patient with absolute erythrocytosis / P. Mossuz, F. Giro-don, M. Donnard [ et al.] // Haematologica. – 2004. - Vol. 89, N 10. – P. 1194-1198.
McMullin M.F. The classification and diagnosis of erythrocytosis / M.F.McMullin // Int. Jnl. Lab. Hem. – 2008. – Vol. 30, N 6. – P. 447-459.
Mesa R. A. Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disor-ders / R. A. Mesa // Hematol. – 2007. – Vol. 93. – P. 355–362.
Patnaik M.M. The complete evaluation of ery-throcytosis: congenital and acquired / M.M. Patnaik, A. Teffery // Leukemia. – 2009. – Vol. 23, N 5. – P. 834-844.
Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recom-mendations from European Leukemia Net / T. Barbui, G. Barosi, G. Birgegard [et al.] // J. Clin. Oncol. – 2011. – Vol. 29, N 6. – P. 761 - 770.
Serum erythropoetin values in erythrocytosis and primary thrombocytaemia / M. Messinezy [ et al.] // Br. J. Hae¬matol. – 2002. – Vol. 117, N 1. – P. 47-53.
Spivak J.L. Polycythemia vera: myths, mecha-nisms and management / J.L. Spivak // Blood. – 2002. – Vol. 100, N 13. – P. 4272-4290.
Tefferi A. Classification and diagnosis of myelo-proliferative neoplasms: The 2008 World Health Orga-nization criteria and point-of-care diagnostic algo¬rithms / A. Tefferi, J. W. Vardiman // Leukemia. – 2008. – Vol. 22. – P. 14–22.
Tefferi A. Myeloproliferative Neoplasms: Mole-cular Pathophysiology, Essential Clinical Understanding, and Treatment Strategies / A.Tefferi, W.Vainchenker // J. Clin. Oncol. – 2011. – Vol. 29, N 2. – P. 573-582.
Thiele J. The 2008 WHO Diagnostic Criteria for Polycythemia Vera, Essential Thrombocythemia, and Pri-mary Myelofibrosis / J.Thiele, H.M. Kvasnicka // Current Hematologic Malignancy Reports. – 2009. – Vol. 4. – Р. 33-40.
Rumjancev AG, Morshhakova EF, Pavlov AD. Jeritropojetin. Biologicheskie svojstva. Vozrastnaja reguljacija jeritropojeza. Klinicheskoe primenenie. M: Gjeotar –med. 2002;399.
Tanasijchuk IS. Algoritm ocenki jeffektivnosti diagnosticheskih kriteriev. Ukr zhurnal gematologії ta transfuzіologії.2010;4:35-39.
Alman DG, Bland JM. Diagnostic test.1: sensitivity and specificity. BMJ. 1994;308;1552.
Mossuz P, Girodon F, Donnard M. Diagnostic value of serum erythropoetin level in patient with absolute erythrocytosis. Haematologica.2004;89(10):1194-8.
McMullin MF. The classification and diagnosis of erythrocytosis. Int Jnl Lab Hem. 2008;30(6):447-59.
Mesa RA. Navigating the evolving paradigms in the diagnosis and treatment of myeloproliferative disorders. Hematol. 2007;93:355–62.
Patnaik MM, Teffery A. The complete evaluation of erythrocytosis: congenital and acquired. Leukemia. 2009;23(5):834-44.
Barbui T, Barosi G, Birgegard G. Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European Leukemia Net. J Clin Oncol. 2011;29(6):761-70.
Messinezy M. Serum erythropoetin values in erythrocytosis and primary thrombocytaemia. Br J Haematol. 2002;117(1):47-53.
Spivak JL. Polycythemia vera: myths, mecha-nisms and management. Blood. 2002;100(13):4272-90.
Tefferi A, Vardiman JW. Classification and diag-nosis of myeloproliferative neoplasms: The 2008 World Health Organization criteria and point-of-care diagnostic algorithms. Leukemia. 2008;22:14–22.
Tefferi A, Vainchenker W. Myeloproliferative Neo¬plasms: Molecular Pathophysiology, Essential Clini-cal Understanding, and Treatment Strategies. J Clin Oncol. 2011;29(2):573-82.
Thiele J, Kvasnicka HM. The 2008 WHO Diag-nostic Criteria for Polycythemia Vera, Essential Throm-bocythemia, and Primary Myelofibrosis. Current Hema-tologic Malignancy Reports. 2009;4:33-40.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2017 Medical Perspectives
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Submitting manuscript to the journal "Medicni perspektivi" the author(s) agree with transferring copyright from the author(s) to publisher (including photos, figures, tables, etc.) editor, reproducing materials of the manuscript in the journal, Internet, translation into other languages, export and import of the issue with the author’s article, spreading without limitation of their period of validity both on the territory of Ukraine and other countries. This and other mutual duties of the author and all co-authors separately and editorial board are secured by written agreement by special form to use the article, the sample of which is presented on the site.
Author signs a written agreement and sends it to Editorial Board simultaneously with submission of the manuscript.
